Breast Cancer

As the Avastin (bevacizumab) drama continues at the FDA, the National Comprehensive Cancer Network (NCCN) has weighed in.

David Pearlstone, M.D. Co-Division Chief, Breast Oncology from John Theurer Cancer Center, on important research taking place in the field of breast oncology.

CYP2D6 phenotype status does not predict tamoxifen efficacy in patients with early-stage breast cancer, according to a retrospective analysis of data from the Breast International Group

Breast cancer researcher Edith A. Perez, MD, is aiming to present more detailed study findings at national conferences later this year that will help clinicians better identify patients who would benefit from HER2 targeted treatment.

Although several endocrine therapies are available today, the authors of this commentary contend that the quest for a better tamoxifen is ongoing.

Two studies presented at SABCS refined knowledge about how to prevent lymphedema in patients with breast cancer.

Debu Tripathy, MD, Co-leader Women's Breast Cancer Program at USC/Norris Comprehensive Cancer Center, on bone health considerations for patients with breast cancer.

Debu Tripathy, MD, Co-leader Women’s Breast Cancer Program at USC/Norris Comprehensive Cancer Center, discusses clinical research and studies looking at the use of bisphosphonate for women with breast cancer.

David Pearlstone, MD, Co-Division Chief, Breast Oncology from John Theurer Cancer Center on Biomarker Testing in the Community Setting

David Pearlstone, M.D. Co-Division Chief, Breast Oncology from John Theurer Cancer Center on Breast Cancer's Surgical Progression in the Past 10 Years

Daniel A. Osman, MD, Founder and Course Director of the Miami Breast Cancer Conference Discusses Methods for Detecting Malignant Conditions in Breast Cancer

David Pearlstone, MD, Co-Division Chief, Breast Oncology from John Theurer Cancer Center on Struggles Facing Breast Oncologists

David Pearlstone, M.D. Co-Division Chief, Breast Oncology from John Theurer Cancer Center on Genomics and Personalized Medicine

David Pearlstone, M.D. Co-Division Chief, Breast Oncology from John Theurer Cancer Center on his Role in Designing new Equipment

Breast pain is among the most common reasons that women seek medical attention from a breast specialist.

Amid advances in gene-based cancer diagnostics, questions about the best use of molecular and cellular assays in practice are growing along with the new options for clinicians.

The FDA is examining a potential link between breast implants and anaplastic large cell lymphoma (ALCL), a rare and aggressive form of non-Hodgkin lymphoma.

Noreen Fraser clearly recalls the day in 2003 when her doctor informed her that the breast cancer she had been diagnosed with 2 years earlier had metastasized to her bones

NCCN Launches Consumer-Friendly Versions of Guideline Publications Breast cancer and non-small cell lung cancer are the inaugural entries in a new series of publications the National Comprehensive Cancer Network (NCCN) is rolling out in the coming months.

The FDA has requested that the generic drug manufacturer Hospira change the planned label for its generic formulation of docetaxel.

The genuine revolution in our understanding of the genetic basis of malignant disease has led to a corresponding interest in defining the risk of developing a particular disease for both individuals and specific populations.